Skip to main content
NC3Rs: National Centre for the Replacement Refinement & Reduction of Animals in Research
Guidance

Organ-on-a-chip technologies

Organ-on-a-chip (OoC) technologies are promising tools to reduce the reliance on animal models in basic and applied research.

Introduction

Organ-on-a-chip (OoC) technologies, also known as microphysiological systems (MPS) or tissue chips, are microfluidic cell culture devices that recapitulate the structure, function and (patho)physiology of human tissues and organs in vitro.

We support the development and uptake of OoC technology through a variety of mechanisms including:

  • Funding research and innovation.
  • Collaborating nationally and internationally.
  • Disseminating opportunities through our events and webinars.

Below you can find out more about our OoC activities as well as other global programmes and initiatives. The aim of these resources is to showcase our portfolio of projects in this area and provide information and support for the community, including technology developers, end-users, regulators and in vivo researchers who are looking to adopt alternative approaches. 

Reports and recommendations

This NC3Rs report, published in 2021, summarises the current OoC landscape and our recommendations for supporting the technology's development and wider adoption.

Summary from a joint OoC workshop, held in 2018, outlining the key focus areas for the UK to advance the technology.

MPSCoRe working group

We have established with NICEATM (the US National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods) a working group to coordinate global efforts for the use of microphysiological systems (organ-on-a-chip and other complex multicellular in vitro models) to reduce reliance on in vivo studies of COVID-19.

Learn more about the MPSCoRe working group in Our portfolio

Funding opportunites

We fund the development and application of OoC technology across our research funding and CRACK IT innovation programmes, and encourage applications in this space. To date we have committed £10.2M funding, which has led to the development of OoC models for assessing kidney and CNS toxicities and ovarian cancer research. Below, you can find out more about the OoC research we have funded.

We fund new model development through our Project grants and early career awards (PhD Studentships and Training Fellowships).

Our Skills and Knowledge Transfer grants support the adoption of established 3Rs technologies through funding collaborations between model developers and end-users.

Our CRACK IT programme champions innovation in the 3Rs, turning great ideas into products and services.

  • If you are an end-user, you may be interested in submitting an idea for a CRACK IT Challenge through our annual open call (e.g. a call for a new product or technology targeted to your needs). Visit the Sponsor a Challenge page on our Innovation Platform website to find out more.
     
  • If you are a technology developer looking to identify new partners and customers to further develop, validate and use your OoC technology then you may be interested in showcasing your technology through the technology partnering platform konfer. Please visit the Technology Partnering page on the Innovation Platform website for further information.

Funded OoC research

To learn more about the OoC technology we have supported through our research funding and CRACK IT programmes, visit Our portfolio

Global programmes and initiatives

Funding and partnerships have been critical in supporting OoC development and moving it towards commercialisation and adoption. The non-exhaustive list below summarises some of the past and on-going global programmes and initiatives in the OoC field. 

The Tissue Chip for Drug Screening Programme

Led by the National Centre for Advancing Translational Sciences, part of the National Institute of Health, this programme was launched in 2012 with the aim to develop tissue chips of human organ systems to better predict drug safety and efficacy. A range of diverse platforms have been developed and two Tissue Chip Testing Centres and a Tissue Chip Database Centre have been established to independently test and validate these platforms. The programme continues to grow focusing on efficacy and disease modelling, personalised medicine, the immune system and tissue chips in space.

Papers describing the programme and outputs:


The Defense Advanced Research Projects Agency (DARPA) microphysiological systems programme

The programme was launched in 2012 with the aim to develop an in vitro platform linking ten or more organ systems together to evaluate the safety and efficacy of novel medical countermeasures (e.g. emerging infectious diseases and chemical or biological attack). Funding was awarded to teams from the Massachusetts Institute of Technology (MIT) and the Wyss Institute, which led to the development of two platforms. The DARPA report summarises the programme and its outputs.

Papers describing the platforms developed:


The Innovation and Quality (IQ) consortium MPS affiliate (IQ MPS affiliate)

A not-for-profit organisation of pharmaceutical and biotechnology companies to facilitate cross-pharma collaboration and data sharing of microphysiological systems (MPS), raising awareness of and supporting MPS qualification and implementation.

A series of papers was published in Lab on a Chip outlining the pharmaceutical industry perspectives and considerations for developing, evaluating and characterisating MPS models to support drug discovery and development – see Fabre et al. (2020).


The North American 3Rs Collaborative (NA3RsC) Microphysiological Systems Initiative

The NA3RsC has established the MPS initiative to encourage collaborations to increase adoption and regulatory acceptance of the technology. The initiative includes representatives from providers of commercial systems and end-users. 


The German GO-Bio multi-organ bioreactor programme

A GO-Bio grant was awarded to the Technisch Universitat Berlin in collaboration with TissUse GmbH and the Fraunhofer IWS in Dresden and the Fraunhofer IGB in Stuttgart.

Papers describing the multi-organ models developed including a human 3D liver and skin model and an ADME chip connecting human intestine, skin, liver and kidney:


EU body-on-a-chip

Funding was awarded to a consortium including InSphero AG (Switzerland), ETH Zurich (Switzerland)), KU Leuven (Belgium), Technical University Dortmund (Germany) and AstraZeneca to develop a device that interconnects multi-organ tissue models. This led to the generation of a plate-base device commercialised by InSphero as the AkuraTM Flow.


The Netherlands Institute for Human Organ and Disease Model Technologies (hDMT)

Initiated in 2015, hDMT is a pre-competitive, not-for-profit technological R&D institute integrating human stem cell technologies with academic and industry expertise to develop human organ and disease models-on-a-chip. Focus areas include vessels-on-chip/vascular disease, heart-on-chip/cardiac diseases, cancer-on-chip and brain-on-chip.


ORgan-on-Chip In Development (ORCHID)

A Horizon 2020 funded EU initiative started in 2017 with the aim of creating an OoC roadmap and building a network of academic, research, industrial and regulatory institutions to move the technologies from the laboratory towards adoption.

The project has finished and the roadmap has been published, outlined in Mastrangeli et al. (2019). The roadmap will continue to be implemented through the European Organ-on-Chip Society established in 2018 as one of the outputs from ORCHID. The Society, a not-for-profit organisation, provides opportunities to share knowledge and expertise in the field, and runs an annual conference.


The Centre for Alternatives to Animal Testing (CAAT)/CAAT Europe T4 Think Tank on MPS

In 2015, a CAAT Transatlantic Think Tank of Toxicology (t4) workshop, brought together global stakeholders to discuss the status of OoC technologies for industry needs and requirements to facilitate adoption and regulatory acceptance. In 2019, a subsequent workshop was held to discuss the barriers that need to be overcome for the technology to be adopted by the pharmaceutical industry and to achieve regulatory acceptance.

  • Summary of the 2015 workshop: Marx et al. (2016)
  • Summary of the recommendations from the 2019 workshop highlighting where the technology has started to be implemented in the pharmaceutical industry and a road map to adoption and regulatory acceptance: Marx et al. (2020)

The UK Organ-on-a-chip Technologies Network

A network funded by the MRC, EPSRC and BBSRC to capture, inspire and grow the UK research activity in the OoC field.


The Japanese Agency for Medical Research and Development

The project aims to develop OoCs populated with cells derived from induced pluripotent stem cells that can be applied for safety and pharmacokinetics in drug discovery, with a focus on liver, intestine, kidney and the blood-brain barrier.

References

  1. Edington CD et al. (2018). Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies. Scientific Reports 8: 4530. doi: 10.1038/s41598-018-22749-0.
  2. Fabre K et al. (2020). Introduction to a Manuscript Series on the Characterization and Use of Microphysiological Systems (MPS) in Pharmaceutical Safety and ADME Applications. Lab on a Chip 20(6): 1049–1057. doi: 10.1039/c9lc01168d  
  3. Herland A et al. (2020). Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips. Nature Biomedical Engineering. doi: 10.1038/s41551-019-0498-9
  4. Low LA and Tagle DA (2017a). Organs-on-chips: Progress, challenges, and future directions. Experimental Biology and Medicine 242(16): 1573–1578. doi: 10.1177/1535370217700523
  5. Low LA and Tagle DA (2017b). Microphysiological Systems (“Organs-on-Chips”) for Drug Efficacy and Toxicity Testing. Clinical and Translational Science 10(4): 237–239. doi: 10.1111/cts.12444
  6. Low LA and Tagle DA (2017c). Tissue Chips - innovative tools for drug development and disease modelling. Lab Chip 17(18): 3026–3036. doi: 10.1039/c7lc00462a
  7. Marx U et al. (2016). Biology-inspired Microphysiological System Approaches to Solve the Prediction Dilemma of Substance Testing. ALTEX- Alternatives to animal experimentation 33(3): 272–321. doi: 10.14573/altex.1603161
  8. Marx U et al. (2020). Biology-inspired microphysiological system to advance medicines for patient benefit and animal welfare. ALTEX- Alternatives to animal experimentation 37(3): 365–394. doi: 10.14573/altex.2001241
  9. Mastrangeli M et al. (2019). Building blocks for a European Organ-on-Chip roadmap. ALTEX- Alternatives to animal experimentation 36(3): 481–492. doi: 10.14573/altex.1905221
  10. Maschmeyer I et al. (2015). A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents. Lab chip 15(12): 2688–2699. doi: 10.1039/c5lc00392j
  11. Novak R et al. (2020). Robotic fluidic coupling and interrogation of multiple vascularized organ chips. Nature Biomedical Engineering. doi: 10.1038/s41551-019-0497-x
  12. Tagle DA (2019). The NIH microphysiological systems program: developing in vitro tools for safety and efficacy in drug development. Current Opinion in Pharmacology 48: 146–154. doi: 10.1016/j.coph.2019.09.007
  13. Wagner I et al. (2013). A dynamic multi-organ chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture. Lab Chip 13(18): 3538–3547. doi: 10.1039/c3lc50234a

A showcase of organ-on-a-chip research funded by the NC3Rs highlighting the technology's scientific and 3Rs benefits. Recorded in 2020.

Illustration showing the various organs that an organ-on-a-chip can model, including the retina, brain, heart, lungs, kidneys and intestines.